DEF: Jazz Pharmaceuticals to Hold 2025 AGM, Seeks Shareholder Approval for Director Elections, Executive Pay, and Share Issuance Authority

Jazz Pharmaceuticals plc has announced its 2025 Annual General Meeting to be held on July 24, 2025, seeking shareholder approval for the election of four directors, ratification of KPMG as auditors, advisory approval of executive compensation, and renewal of authority to allot shares for cash without pre-emption rights.

Summary

• The 2025 Annual General Meeting (AGM) of Jazz Pharmaceuticals plc will be held on Thursday, July 24, 2025, at 9:45 a.m. local time in Dublin, Ireland.
• Shareholders will vote on four key proposals: the election of four director nominees (Jennifer E. Cook, Patrick G. Enright, Seamus Mulligan, and Norbert G. Riedel, Ph.D.) to serve until the 2028 AGM, the ratification of KPMG as independent auditors for fiscal year 2025 and authorization of their remuneration, a non-binding advisory vote on named executive officer (NEO) compensation, and a special resolution to grant the Board authority to allot and issue ordinary shares for cash without first offering them to existing shareholders.
• For fiscal year 2024, the company reported strong commercial performance with Xywav net product sales of $1,473.2 million (up 16% over 2023), Epidiolex/Epidyolex net product sales of $972.4 million (up 15% over 2023), Rylaze/Enrylaze net product sales of $410.8 million (up 4% over 2023), and Zepzelca net product sales of $320.3 million (up 11% over 2023).
• The overall corporate achievement for the 2024 annual performance bonus program was 112% of target.
• The 2022-2024 Performance-Based Restricted Stock Unit (PSU) award cycle resulted in a final payout of 66% of target, influenced by a 43rd percentile Total Shareholder Return (TSR) ranking against peers.
• The company successfully completed a Biologics License Application (BLA) submission for zanidatamab in second-line Biliary Tract Cancer (BTC) and received accelerated FDA approval, launching Ziihera in the U.S. in December 2024.
• CEO Bruce C. Cozadd plans to retire by the end of 2025, with a Succession Committee leading the search for a successor; Mr. Cozadd intends to continue as Chairperson of the Board.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook on the company's performance, strategic direction, and governance. Strong product sales growth and significant pipeline advancements are highlighted. While some performance metrics for executive bonuses were below maximum, the overall corporate achievement was above target. The request for share issuance authority is framed as a strategic necessity for growth and M&A, indicating proactive management. The tone is confident and forward-looking, emphasizing value creation and robust governance.

Positives

• Strong commercial performance with Xywav net product sales increasing 16% to $1,473.2 million in 2024.
• Epidiolex/Epidyolex net product sales grew 15% to $972.4 million in 2024, demonstrating continued adoption.
• Successful accelerated FDA approval and U.S. launch of Ziihera (zanidatamab) for previously treated HER2-positive BTC in 2024, expanding the oncology portfolio.
• Achievement of 7 out of 8 top-priority pipeline program goals for 2024, contributing significantly to performance-based compensation metrics.
• Overall corporate achievement for the 2024 annual performance bonus program was 112% of target, indicating strong execution against objectives.
• Active Board refreshment program with five new independent directors appointed since 2019, enhancing diverse skills and perspectives.
• High level of board independence, with 11 out of 12 current directors identified as independent.
• Robust corporate governance practices, including executive and director share ownership guidelines, an anti-hedging/pledging policy, and a formal clawback policy.
• Strong shareholder support for the executive compensation program, with approximately 91% approval at the 2024 AGM.
• Commitment to Environmental, Social, and Governance (ESG) initiatives, including a completed double materiality assessment and preparation for EU Corporate Sustainability Reporting Directive (CSRD) compliance.

Negatives

• Combined Epidiolex/Epidyolex and oncology net product sales, while growing, were between threshold and target for bonus calculation, resulting in a 98% multiplier.
• Xywav (Idiopathic Hypersomnia) patients on therapy exiting 2024 were between threshold and target for bonus calculation, leading to a lower multiplier.
• One top-priority pipeline goal, the Epidiolex/Epidyolex Japan study, did not meet its primary endpoint.
• Strategic add-on goals for pipeline and transformation objectives were not awarded, indicating some unachieved discretionary targets.
• Non-GAAP adjusted operating margin of 42.8% was slightly below the target of 43.3% for bonus calculation, resulting in a 79% payout multiplier for this component.
• The 2022-2024 PSU award cycle's final payout of 66% of target was reduced by 5% due to the company's Total Shareholder Return (TSR) ranking in the 43rd percentile against peers.

Risks

• Maintaining or increasing sales and revenue from key marketed products such as Xywav, Rylaze, and Epidiolex/Epidyolex.
• The introduction of new products into the U.S. market that could compete with or disrupt the market for existing products and product candidates.
• Compliance with regulatory restrictions, including the requirements of risk evaluation and mitigation strategies for oxybate products and safety reporting.
• Successfully completing development and regulatory activities for product candidates.
• Obtaining and maintaining adequate coverage and reimbursement for products.
• Increasing scrutiny regarding pricing and global trends towards healthcare cost containment.
• Market acceptance of products by physicians, patients, third-party payors, and the medical community.
• The time-consuming and uncertain regulatory approval process, with risks that current and/or planned regulatory submissions may not be submitted, accepted, or approved timely or at all.
• The costly and time-consuming nature of pharmaceutical product development and the inherent uncertainty of clinical success, including risks related to failure or delays in initiating or completing clinical trials.
• Global economic, financial, and healthcare system disruptions and their potential negative impacts on business operations and financial results.
• Geopolitical events, including the conflict between Russia and Ukraine and related sanctions.
• Macroeconomic conditions, such as fluctuations in interest rates, inflation, and recent banking disruptions.
• Regulatory initiatives and changes in tax laws.
• Market volatility affecting share price.
• Protecting and enhancing intellectual property rights, as commercial success depends on obtaining, maintaining, and defending intellectual property protection.
• Delays or problems in the supply or manufacture of products and product candidates.
• Significant disruptions of information technology systems or data security incidents.
• Complying with applicable U.S. and non-U.S. regulatory requirements, particularly those governing controlled substances.
• Government investigations, legal proceedings, and other actions.
• Identifying and consummating corporate development transactions, financing these transactions, and successfully integrating acquired product candidates, products, and businesses.
• The ability to realize the anticipated benefits of business development transactions, collaborations, and license agreements with third parties.
• The sufficiency of cash flows and capital resources.
• Challenges inherent in efficiently managing employees in diverse geographies and maintaining a positive workplace culture.
• The aspirational nature of Corporate Sustainability and Social Impact (CSSI) strategies, efforts, and initiatives, which are not guarantees.
• The ability to meet projected long-term goals and objectives within anticipated time periods or at all, given the inherent uncertainty and significant judgments and assumptions.
• The ability to identify, compete with others for, and successfully complete any potential future business development transactions.

Future Outlook

Jazz Pharmaceuticals aims for continued growth and diversification of its portfolio and revenues, driven by commercial launches, robust R&D programs, and strategic corporate development. The company is actively searching for a successor CEO, with current CEO Bruce C. Cozadd planning to retire by the end of 2025 but continue as Chairperson. The company is also preparing for upcoming sustainability and ESG reporting regulations, including CSRD, and integrating results from a double materiality assessment into its CSSI strategy and ERM.

Management Comments

• "Our total revenue growth was led by the strength of our marketed therapies, including the continued adoption of Xywav across both narcolepsy and idiopathic hypersomnia, meaningful Epidiolex growth, and continued demand for Rylaze."
• "Building on several transformative years for R&D at our Company, we have enhanced the breadth and depth of our pipeline, as well as our development capabilities."
• "Our Board is soliciting your proxy to vote at our 2025 AGM. Our proxy statement contains important information for you to consider when deciding how to vote on the matters brought before our 2025 AGM." (Aislinn Doody, Company Secretary)
• "Our Company is committed to governance policies and practices that serve the best interests of our Company and enhance shareholder value over the long term."
• "Our Board plays a crucial role in overseeing our long-term corporate strategy, approving strategic plans, monitoring performance with key metrics, allocating resources effectively, and making informed investment decisions."
• "Our Board has been preparing for Mr. Cozadd's transition through rigorous succession planning efforts. As part of a thorough and diligent process, a Succession Committee of our Board, made up of independent directors, has been set up to lead a comprehensive and thoughtful search for the next CEO, which we intend to complete in 2025."
• "Our Compensation Committee concluded that our shareholders continue to support our executive compensation program and that it continues to provide a competitive pay-for-performance package that effectively incentivizes the NEOs and encourages long-term retention."
• "Granting our Board the pre-emption opt-out authority on the terms set forth in this Proposal 4 is vital to advancing our business and driving shareholder value, including, if applicable, in connection with potential capital raising and corporate development transactions."

Industry Context

Jazz Pharmaceuticals operates within the highly competitive biopharmaceutical industry, focusing on commercial products and a robust R&D pipeline. The company's strategy emphasizes growth through commercialization, R&D advancements, and strategic corporate development, including potential acquisitions. Its executive compensation peer group consists of other publicly traded biotechnology and specialty biopharma companies with commercial products, reflecting the competitive landscape for talent. The company also highlights its commitment to ESG reporting, aligning with emerging European regulations like CSRD, indicating a broader industry trend towards increased sustainability disclosure.

Comparison to Industry Standards

• The executive compensation peer group for 2024 consisted of 13 companies in the life sciences industry (biotechnology and specialty biopharma) with commercial products, revenues generally 0.5x to 3x Jazz's projected revenue ($1.9 billion $11.2 billion), and market value 0.3x to 4x Jazz's market capitalization ($2.7 billion $32.2 billion).
• At the time of peer group approval, Jazz was at the 59th percentile for trailing 12 months revenue and the 21st percentile for market capitalization within this peer group, indicating it is a smaller-cap company relative to some peers but with solid revenue.
• The Nasdaq Biotechnology Index is used as the peer group for calculating relative TSR in PSU awards, chosen for its size, common use as a comparator, and alignment with Jazz's profile in terms of revenue, market capitalization, and volatility.
• The company's CEO pay ratio of 55 to 1 is disclosed, with the caveat that SEC rules for this calculation allow for different methodologies, making direct comparisons across companies difficult.
• The company's classified board structure is noted as promoting stability and continuity, while acknowledging that some shareholders may view it as an entrenchment risk, which is mitigated by Irish law allowing shareholder removal of directors.
• The request for pre-emption opt-out authority is highlighted as an Irish law requirement not typically faced by U.S.-incorporated companies, potentially putting Jazz at a disadvantage in competitive M&A.

Management Changes

Corporate Governance

Related Party Transactions

• A family member of Class I director Laura J. Hamill is employed by the Company, not as an executive officer. Total compensation for this employee was approximately $416,000 for fiscal year 2024, determined in accordance with company policies for similar roles.

Stakeholder Impact

• Shareholders: Directly impacted by proposals for director elections, executive compensation, and share issuance authority, with emphasis on aligning executive pay with shareholder value and robust governance.
• Employees: Affected by executive compensation policies, talent development, succession planning, and a focus on corporate culture and human capital management, including participation in 401(k) and ESPP.
• Patients: Central to the company's CSSI strategy, with efforts to advance patient-focused strategies, incorporate patient insights, and provide patient assistance programs.
• Customers/Healthcare Community: Engaged through commercialization efforts for marketed therapies and R&D initiatives for new products.
• Suppliers/Business Partners: Expected to adhere to the company's Code of Conduct and Ethics, with procedures to assess compliance with anti-slavery and human trafficking laws.
• Regulatory Authorities: Company operates in a highly regulated industry, with ongoing compliance efforts and disclosures to SEC and other bodies.

Next Steps

• Hold 2025 Annual General Meeting on July 24, 2025.
• Elect four director nominees at the 2025 AGM.
• Shareholders to ratify KPMG's appointment and authorize remuneration.
• Shareholders to vote on executive compensation (say-on-pay).
• Shareholders to vote on Board authority to allot and issue ordinary shares for cash without pre-emption rights.
• Management to present and auditors to report on Irish financial statements for fiscal year ended December 31, 2024, at the AGM.
• Bruce C. Cozadd plans to retire as CEO by the end of 2025, with a Succession Committee leading the search for a successor.
• Company to continue integrating double materiality assessment results into CSSI strategy, ERM, and reporting.
• 2024 CSSI Report to be available on the company website by end of June 2025.
• Next advisory vote on NEO compensation at the 2026 AGM.
• Expect to propose renewal of Board's pre-emption opt-out authority at the 2026 AGM.

Key Dates

Recommendation

Keywords

Jazz Pharmaceuticals, Proxy Statement, SEC Filing, Annual General Meeting, Director Election, Executive Compensation, Corporate Governance, Biotechnology, Pharmaceuticals, Xywav, Epidiolex, Rylaze, Zepzelca, Ziihera, Zanidatamab, Pipeline Development, Research and Development, Financial Performance, Risk Management, Capital Allocation, Share Issuance Authority, Pre-emption Rights, Nasdaq Biotechnology Index, ESG, CSSI, CEO Succession